BIOVAXYS ANNOUNCES SHARE CONSOLIDATION

Core Viewpoint - BioVaxys Technology Corp. is consolidating its common shares at a ratio of ten pre-consolidation shares for one post-consolidation share, effective September 11, 2025 [1][2][3]. Share Consolidation Details - The company currently has 293,425,203 common shares outstanding, which will reduce to approximately 29,342,496 shares post-consolidation [3]. - No fractional shares will be issued; any fractions will be rounded up or down to the nearest whole share [3]. - The exercise price and number of shares for outstanding convertible securities will be proportionately adjusted [3]. Shareholder Actions - Registered shareholders with physical certificates must send their pre-consolidation shares along with a completed letter of transmittal to the transfer agent [4]. - Shareholders without physical certificates will automatically receive a new DRS advice for the post-consolidation shares [5]. Regulatory Approval - The consolidation was approved by the company's board of directors and is subject to the approval of the Canadian Securities Exchange (CSE) [6].